Title: Continuous Manufacturing Gains Major Push from FDA

FDA is moving to shift industry away from step-wise batch production. Apr 02, 2019 By Jill Wechsler Pharmaceutical Technology Volume 43, Issue 4, pg 14–15 Regulatory authorities in the United States and other regions are encouraging investment in continuous manufacturing (CM) processes to better ensure quality drug production, avoid shortages, and ultimately lower the cost of medications for patients. The aim is to support an industry shift away from step-wise batch production, which is vulnerable to contamination, errors, and stoppages, to the use of automated modular systems better able to reduce human error, waste, and delays.

Click Here For Complete Article Text

 

   Person Information
   Application Sequencing
 325412 - Pharmaceutical Preparation Manufacturing                
Company  Product  Process  Other  Subjects  Event  Event  Date  Location  Publication  Publication  Date Text  Descriptor

  • Contract Manufacturing

 

 

 

 

  • Pharmaceutical Technology

 

  • 4/1/2019

 

  • Article